ERBB2 and colorectal carcinoma: A study from Germany indicated that HER2 amplification resulted in poorer prognosis in all stage CRC (Ingold Heppner et al., 2014), and Laurentpuig et al. (2016) found that HER2 amplification was significantly associated with worse prognosis in patients with stage III CRC.